-
公开(公告)号:US20120052130A1
公开(公告)日:2012-03-01
申请号:US13318152
申请日:2010-04-12
申请人: Etzer Darout , Michael Paul DeNinno , Kentaro Futatsugi , Cristiano Ruch Werneck Guimaraes , Bruce Allen Lefker , Vincent Mascitti , Kim Francis McClure , Michael John Munchhof , Ralph Pelton Robinson, JR.
发明人: Etzer Darout , Michael Paul DeNinno , Kentaro Futatsugi , Cristiano Ruch Werneck Guimaraes , Bruce Allen Lefker , Vincent Mascitti , Kim Francis McClure , Michael John Munchhof , Ralph Pelton Robinson, JR.
IPC分类号: A61K35/56 , A61K31/506 , A61K31/497 , A61K31/55 , A61K31/536 , A61K31/566 , A61K38/22 , A61K31/4985 , A61K31/4965 , A61K38/16 , A61K31/715 , A61K38/26 , A61K31/513 , A61K31/706 , A61K31/517 , A61P3/10 , A61P3/04 , A61P3/08 , A61P3/06 , A61P9/10 , A61P9/00 , A61P19/02 , A61P19/10 , A61P13/12 , A61P7/02 , A61P25/28 , A61P25/18 , A61P25/00 , A61P1/00 , C07D239/47
CPC分类号: C07D471/04 , C07D401/14 , C07D491/08
摘要: Compounds of Formula (I) that modulate the activity of the G-protein-coupled receptor GPFM 19 and their uses in the treatment of diseases linked to the modulation of the G-protein-coupled receptor GPR119 in animals are described herein.
摘要翻译: 本文描述了调节G-蛋白偶联受体GPFM19的活性的式(I)化合物及其在治疗与动物中G蛋白偶联受体GPR119的调节相关的疾病中的用途。
-
公开(公告)号:US20120095028A1
公开(公告)日:2012-04-19
申请号:US13257384
申请日:2010-03-04
申请人: Michael Paul DeNinno , Kentaro Futatsugi , Bruce Allen Lefker , Vincent Mascitti , Kim Francis McClure , Michael John Munchhof
发明人: Michael Paul DeNinno , Kentaro Futatsugi , Bruce Allen Lefker , Vincent Mascitti , Kim Francis McClure , Michael John Munchhof
IPC分类号: A61K31/519 , A61P13/00 , A61P3/00 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/00 , A61P19/02 , A61P19/10 , A61P9/12 , A61P13/12 , A61P15/00 , A61P9/10 , A61P15/10 , A61P17/00 , A61P25/28 , A61P25/18 , A61P1/00 , C07D471/04
CPC分类号: C07D491/08 , A61K31/519 , A61K45/06 , A61K2300/00
摘要: Compounds of Formula (I) that modulate the activity of the G-protein-coupled receptor GPR119 and their uses in the treatment of diseases linked to the modulation of the G-protein-coupled receptor GPR119 in animals are described herein.
摘要翻译: 本文描述了调节G-蛋白偶联受体GPR119的活性的式(I)化合物及其在治疗与动物中G蛋白偶联受体GPR119的调节相关的疾病中的用途。
-
公开(公告)号:US06303636B1
公开(公告)日:2001-10-16
申请号:US09355163
申请日:1999-07-22
IPC分类号: A61K31445
CPC分类号: C07D409/04 , C07C311/20 , C07C311/29 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07D205/04 , C07D211/66
摘要: A compound of the formula wherein R1, R2 and Q are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF. In addition, the compounds of the present invention may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (NSAID'S) and analgesics, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and other alkaloids, such as vincristine, in the treatment of cancer,
摘要翻译: 式R 1,R 2和Q的化合物如上所定义,可用于治疗选自关节炎,癌症,组织溃疡,黄斑变性,再狭窄,牙周病,大疱性表皮松解症,巩膜炎等的病症 以基质金属蛋白酶活性为特征的疾病,艾滋病,败血症,败血性休克和涉及TNF产生的其他疾病。 此外,本发明的化合物可以与标准的非甾体抗炎药(NSAID'S)和止痛剂组合使用,并与细胞毒性药物如阿霉素,道诺霉素,顺铂,依托泊苷,紫杉醇, 泰索帝等生物碱,如长春新碱,治疗癌症,
-
-